POLBF (Poolbeg Pharma) Retained Earnings: $-30.04 Mil (As of Dec. 2025)


What is Poolbeg Pharma Retained Earnings?

Poolbeg Pharma POLBF Retained Earnings is $-30.04 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Poolbeg Pharma's retained earnings for the quarter that ended in Dec. 2025 was $-30.04 Mil.

Poolbeg Pharma's quarterly retained earnings declined from Dec. 2024 ($-21.17 Mil) to Jun. 2025 ($-25.67 Mil) and declined from Jun. 2025 ($-25.67 Mil) to Dec. 2025 ($-30.04 Mil).

Poolbeg Pharma's annual retained earnings declined from Dec. 2023 ($-13.87 Mil) to Dec. 2024 ($-21.17 Mil) and declined from Dec. 2024 ($-21.17 Mil) to Dec. 2025 ($-30.04 Mil).

Poolbeg Pharma  (OTCPK:POLBF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Poolbeg Pharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Retained Earnings Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
-3.11 -8.55 -13.87 -21.17 -30.04

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only -13.87 -16.81 -21.17 -25.67 -30.04

Poolbeg Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-30.04 Mil mean?
Poolbeg Pharma (POLBF) has a Retained Earnings of $-30.04 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Retained Earnings too high?
Poolbeg Pharma's current Retained Earnings is $-30.04 Mil.
How does Poolbeg Pharma's Retained Earnings compare to VRTX and REGN?
Poolbeg Pharma's Retained Earnings of $-30.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Retained Earnings is $-30.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Retained Earnings of $-30.04 Mil. The current Retained Earnings is $-30.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Retained Earnings is $-30.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.